A comprehensive league table of cost-utility ratios and a sub-table of "Panel-worthy" studies

被引:124
作者
Chapman, RH
Stone, PW
Sandberg, EA
Bell, C
Neumann, PJ
机构
[1] Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Program Econ Evaluat Med Technol, Boston, MA 02115 USA
[2] Univ Rochester, Sch Nursing Community & Prevent Med, Rochester, NY USA
[3] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada
[4] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA
关键词
cost-utility analysis; league tables; economic evaluation;
D O I
10.1177/0272989X0002000409
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives. The authors compiled a comprehensive league table of cost/QALY ratios, and a standardized table of analyses satisfying selected Reference Case criteria from the USPHS Panel on Cost-Effectiveness in Health and Medicine. Methods. They identified 228 cost-utility analyses (CUAs) through literature searches, and abstracted data on methods and cost-utility ratios. The subset of "Panel-worthy" analyses used: a societal or broad health-care perspective, community or patient preference weights, net costs, incremental comparisons, and discounting of costs and QALYs. Results. The 228 CUAs included ratios for 647 interventions, ranging from cost-saving to $52,000,000/QALY (median = $12,0001QALY). The standardized table presents 112 ratios that met the "Panel-worthy" criteria, with articles published in recent years more likely to meet all of the criteria. Conclusions. The comprehensive league table (available on the Web) provides a useful reference, but ratios may not be comparable because of methodologic variations. The standardized table focuses on studies meeting basic methodologic criteria, potentially allowing for better comparison with future Reference Case analyses. Future studies should investigate the quality of analyses' underlying assumptions in addition to whether certain key procedural protocols were met.
引用
收藏
页码:451 / 467
页数:17
相关论文
共 65 条
  • [11] Cost-effectiveness of screening for asymptomatic carotid atherosclerotic disease
    Derdeyn, CP
    Powers, WJ
    [J]. STROKE, 1996, 27 (11) : 1944 - 1950
  • [12] COST-EFFECTIVENESS LEAGUE TABLES - MORE HARM THAN GOOD
    DRUMMOND, M
    TORRANCE, G
    MASON, J
    [J]. SOCIAL SCIENCE & MEDICINE, 1993, 37 (01) : 33 - 40
  • [13] Ebell MH, 1997, J FAM PRACTICE, V44, P545
  • [14] Comorbidity measures for use with administrative data
    Elixhauser, A
    Steiner, C
    Harris, DR
    Coffey, RN
    [J]. MEDICAL CARE, 1998, 36 (01) : 8 - 27
  • [15] HEALTH-CARE CBA CEA - AN UPDATE ON THE GROWTH AND COMPOSITION OF THE LITERATURE
    ELIXHAUSER, A
    LUCE, BR
    TAYLOR, WR
    REBLANDO, J
    [J]. MEDICAL CARE, 1993, 31 (07) : JS1 - JS11
  • [16] ELIXHAUSER A, 1993, MED CAR, V36, pMS18
  • [17] *FED RES BANK ST L, 1999, MONTHL EXCH RAT SER
  • [18] A COST-UTILITY ANALYSIS OF MISOPROSTOL PROPHYLAXIS FOR RHEUMATOID-ARTHRITIS PATIENTS RECEIVING NONSTEROIDAL ANTIINFLAMMATORY DRUGS
    GABRIEL, SE
    CAMPION, ME
    OFALLON, WM
    [J]. ARTHRITIS AND RHEUMATISM, 1994, 37 (03): : 333 - 341
  • [19] GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1339
  • [20] Raising the quality of cost-utility analyses: lessons learnt and still to learn
    Gerard, K
    Smoker, I
    Seymour, J
    [J]. HEALTH POLICY, 1999, 46 (03) : 217 - 238